Shaanxi University of Chinese Medicine, china.
Shaanxi Hospital of Traditional Chinese Medicine, China.
Rev Esp Enferm Dig. 2023 Apr;115(4):168-174. doi: 10.17235/reed.2022.8863/2022.
Vonoprazan is a potassium competitive acid blocker (P-CAB) approved in Japan in 2014 to treat endoscopic submucosal dissection (ESD)-induced ulcers and bleeding or perforation. Therefore, this meta-analysis aimed to determine whether Vonoprazan is more effective than Lansoprazole in the treatment of ESD-induced ulcers which include ulcer healing and shrinking rate, among others.
Randomized controlled trials (RCT) and retrospective studies were collected from the PubMed (Medline), Embase, Web of science and Cochrane Library databases. Meanwhile, studies were selected according to predetermined qualification criteria and data were extracted by two researchers. The quality of the methods for published papers was evaluated using the modified Jadad scale.
Five studies were included in this meta-analysis, the ulcer healing rate effect was not significantly higher in the intervention groups than in the control groups at 4 weeks, [OR：1.07 (0.51, 2.22), 95% CI, I2=2%, Z=0.18, P=0.86]. There was no significant difference in the ulcer shrinkage rate at 4 weeks [MD：0.20 (-1.51, 1.92), 95% CI, I2=0%, P=0.82] and 8 weeks [MD: -0.09 (-0.30, 0.12), 95% CI, I2=0%, P=0.39].
There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD.
沃诺拉赞是一种钾离子竞争性酸阻滞剂（P-CAB），于 2014 年在日本获批用于治疗内镜黏膜下剥离术（ESD）引起的溃疡以及出血或穿孔。因此，本荟萃分析旨在确定沃诺拉赞在治疗 ESD 引起的溃疡方面是否优于兰索拉唑，包括溃疡愈合率和缩小率等。
从 PubMed（Medline）、Embase、Web of science 和 Cochrane Library 数据库中收集随机对照试验（RCT）和回顾性研究。同时，根据预定的资格标准选择研究，并由两名研究人员提取数据。使用改良 Jadad 量表评估已发表论文方法的质量。
本荟萃分析纳入了 5 项研究，干预组在 4 周时的溃疡愈合率效果并不明显高于对照组[OR：1.07（0.51，2.22），95%CI，I2=2%，Z=0.18，P=0.86]。在 4 周[MD：0.20（-1.51，1.92），95%CI，I2=0%，P=0.82]和 8 周[MD：-0.09（-0.30，0.12），95%CI，I2=0%，P=0.39]时，溃疡缩小率也没有显著差异。
在 ESD 治疗后 4 周和 8 周时，沃诺拉赞与兰索拉唑在溃疡方面没有显著差异。
